Angion Biomedica Corp. has synthesized prodrugs of terevalefim acting as hepatocyte growth factor (HGF) mimetics and reported to be useful for the treatment of renal ischemia-reperfusion and lung injury.
Sunovion Pharmaceuticals Inc. has identified chroman and benzofuran derivatives acting as 5-HT1A and trace amine-associated receptor 1 (TAAR1) agonists reported to be useful for the treatment of depression.
Kawasaki Gakuen has divulged pyrrole-imidazole polyamides acting as transmembrane 4 L6 family member 1 (TM4SF1) and TMEM132b expression inhibitors reported to be useful for the treatment of cancer metastasis.
Inipharm Inc. has divulged thiazoles/isothiazoles acting as 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13) inhibitors reported to be useful for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, cirrhosis, alcoholic liver disease, drug-induced liver injury and portal hypertension.
Stanford University and Acurex Therapeutics Corp. have discovered voltage-dependent T-type calcium channel subunit α-1H (Cav3.2) blockers reported to be useful for the treatment of neurodegeneration.
Standigm Inc. has disclosed leucine-rich repeat kinase 2 (LRRK2), particularly LRRK2 G2019S mutant, inhibitors reported to be useful for the treatment of cancer, neurodegeneration, rheumatoid arthritis, tuberculosis, axial spondyloarthritis, radiographic (ankylosing spondylitis), Crohn's disease and dyskinesia.
RSS